Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire MiroBio Ltd for approximately $410 million on August 4, 2022. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Cowen is acting as financial advisor to Gilead.

Centerview Partners is acting as financial advisor to MiroBio. Davis Polk & Wardwell LLP, Mayer Brown LLP, and Mishcon de Reya LLP are serving as legal counsel to Gilead, and Goodwin Procter LLP and Wilson Sonsini Goodrich & Rosati are serving as legal counsel to MiroBio.